NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
No Result
View All Result
Home ALL Healthcare

Boston Scientific Announces Agreement to Acquire Devoro Medical, Inc.

by Ed Johnson
September 22, 2021
A A

Company to add mechanical thrombectomy platform to peripheral interventions portfolio

MARLBOROUGH, Mass., Sept. 21, 2021 /PRNewswire/ — Today, Boston Scientific Corporation (NYSE: BSX) announced an agreement to acquire Devoro Medical, Inc., developer of the WOLF Thrombectomy® Platform. The innovative non-console and lytic-free WOLF technology targets and rapidly captures blood clots using finger-like prongs that retrieve and remove thrombi in the arterial and venous systems.

“The addition of the WOLF platform advances our efforts to ensure physicians have the right tools to improve procedural efficiencies,” said Jeff Mirviss, executive vice president and president, Peripheral Interventions, Boston Scientific. “Clot management remains a core focus of our business, and upon commercialization, this highly differentiated technology will complement and expand our offerings to a full suite of interventional strategies for thromboemboli, which also includes the EkoSonic™ Endovascular System (EKOS) and the AngioJet™ Thrombectomy System.”

Boston Scientific has been a strategic investor in Devoro Medical since 2019 and currently holds an equity stake of approximately 16 percent. As a result, the transaction consists of an upfront payment of approximately $269 million for the 84 percent stake not yet owned and up to $67 million upon achievement of certain clinical and regulatory milestones.+

“The WOLF platform is a compelling new option for physicians performing thrombectomy procedures and, importantly, it is designed to target and remove clots without damaging blood vessels, while also minimizing blood-loss, which may improve outcomes,” said Michael R. Jaff, D.O., chief medical officer and vice president of clinical affairs, technology and innovation, Peripheral Interventions, Boston Scientific. “We look forward to accelerating the progress of this platform technology so that we help patients who are dealing with these common, yet challenging health conditions.”

On an adjusted basis, the transaction is expected to be slightly dilutive to earnings per share (EPS) in 2021, which Boston Scientific expects to offset via internal cost efficiencies and trade-offs. On a GAAP basis, the transaction will be less dilutive due to a one-time gain to be recognized at closing associated with our previously held equity interest in Devoro Medical. In 2022, the transaction is not expected to impact adjusted EPS and will be slightly dilutive on a GAAP basis due to amortization expense and acquisition-related charges. The transaction is anticipated to close in the fourth quarter of 2021, subject to customary closing conditions.

+Preceding consideration of current equity ownership, debt and other closing adjustments, the transaction price consists of $320 million up front, and up to $80 million upon achievement of certain clinical and regulatory milestones.

Tags: < Invest | M&A
ShareTweetShareSend

Related Industries

Healthcare

Thermo Fisher Scientific Releases 2022 Corporate Social Responsibility Report

May 18, 2023
Healthcare

Medtronic AccuRhythm AI technology receives 2023 MedTech Breakthrough Award as Best New Monitoring Solution

May 17, 2023
Healthcare

Amgen Responds to Ftc Action RE: Proposed Acquisition Of Horizon Therapeutics

May 17, 2023
Healthcare

Cardinal Health Canada to open new distribution center in Ontario

May 11, 2023
Healthcare

Thermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next Generation Sequencing-Based Testing for Cancer Patients in International Markets

May 10, 2023
Healthcare

Lilly’s Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation

May 10, 2023

Toshiba Named a Major Player in the IDC MarketScape “Worldwide Retail Commerce Platform Software Providers 2023 Vendor Assessment”

May 17, 2023

...

Apple’s Worldwide Developers Conference to kick off June 5, 2023, with keynote address

May 24, 2023

...

US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vaccine for older adults

May 4, 2023

...

Blackstone Acquires International Gemological Institute (IGI)

May 22, 2023

...

Kimberly-Clark Professional Announces Greenovation Awards For Sustainability Leadership And Waste Reduction

May 6, 2023

...

DuPont Publishes 2023 Sustainability Report

May 2, 2023

...

3M enters agreements with Pierrel for the sale of assets associated with the dental local anesthetic business

May 3, 2023

...

DuPont Earns Great Place to Work Certification™

May 18, 2023

...

KKR to Acquire Leading Testing and Measurement Instrument Provider Industrial Physics from Union Park Capital

May 12, 2023

...

NORTH AMERICAN BUSINESS (www.na-biz.com) is a leading source of business and corporate news, information, industry trends, market updates and insights across a broad spectrum of industries in North America and worldwide.

MENU

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor#na-biz.com

PARTNERSHIP:     biz#na-biz.com

HUMAN RESOURCE:     hr#na-biz.com

* (replace # with @)

  • Official Site

Copyright © NA-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © NA-BIZ.COM All rights reserved.